Endocrinology, Diabetes & Metabolism Case Reports (May 2020)

Inhibin A as a tumor marker for primary bilateral macronodular adrenal hyperplasia

  • Rachel Wurth,
  • Crystal Kamilaris,
  • Naris Nilubol,
  • Samira M Sadowski,
  • Annabel Berthon,
  • Martha M Quezado,
  • Fabio R Faucz,
  • Constantine A Stratakis,
  • Fady Hannah-Shmouni

DOI
https://doi.org/10.1530/EDM-20-0006
Journal volume & issue
Vol. 1, no. 1
pp. 1 – 6

Abstract

Read online

Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a rare cause of ACTH-independent Cushing syndrome (CS). This condition is characterized by glucocorticoid and/or mineralocorticoid excess, and is commonly regulated by aberrant G-protein coupled receptor expression may be subclinical, allowing the disease to progress for years undetected. Inhibin A is a glycoprotein hormone and tumor marker produced by certain endocrine glands including the adrenal cortex, which has not been previously investigated as a potential tumor marker for PBMAH. In the present report, serum inhibin A levels were evaluated in three patients with PBMAH before and after adrenalectomy. In all cases, serum inhibin A was elevated preoperatively and subsequently fell within the normal range after adrenalectomy. Additionally, adrenal tissues stained positive for inhibin A. We conclude that serum inhibin A levels may be a potential tumor marker for PBMAH.

Keywords